High Prevalence of *Helicobacter pylori* Infection, Atrophic Gastritis and Hypochlorhydria in HIV-Positive Cameroonian Tested by Serological Stomach-Specific Biomarkers (GastroPanel®)

Alonge Ivo Ebule¹,²*, Valentine Ngum Ndze³, Ngouana Kammalac Thierry⁴, Lebongo Belayang Marie², Mbopiwou Nfou Nsimila², Sonkwe Phalone Aurelli², Longdoh Anna Njunda³, Noah Noah Dominique⁵, Marie Claire Okomo Assoumou⁶, Paloheimo Lea⁷ and Kari Syrjänen⁸

¹Faculty of Science, University of Buea, Cameroon.  
²School of Laboratory Technologies, Yaounde, Cameroon.  
³Faculty of Health Sciences, University of Buea, Cameroon.  
⁴Antimicrobial and Biocontrol Agent Unit, University of Yaounde, Cameroon.  
⁵Faculty of Medicine and Pharmaceuticals Sciences, University of Douala, Cameroon.  
⁶Faculty of Medicine and Biomedical Sciences, University of Yaounde, Cameroon.  
⁷Department of Clinical Research, Biohit Oyj, Helsinki, Finland.  
⁸Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.

Authors’ contributions

This work was carried out in collaboration among all authors. Author AIE conceptualized and together with author VNN, designed the study. Authors AIE, VNN, NKT, LBM, MNI and SPA carried out sample collection, analysis, interpreted the data and drafted the manuscript. Authors LAN, NND, PL and KS provided technical advice and corrected the manuscript. Author KS is the director of this work and responsible for the general supervision of the study. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMB/2021/v21i230326

Editor(s):

(1) Dr. Pankaj Kumar , Dolphin (PG) Institute of Biomedical and Natural Sciences, India.  
(2) Dr. Niranjali Perera, Wayamba University of Sri Lanka, Sri Lanka.  

Reviewers:

(1) Selvi Radhakrishnan, Sir Ramachandra Institute of Higher Education and Research (SRIHER), India.  
(2) Lombardo Lucio, Italy.  
(3) Mohamed Mousa Abd El-Mawgoud Eid, Al-Azhar University, Egypt.

Complete Peer review History: [http://www.sdiarticle4.com/review-history/64101](http://www.sdiarticle4.com/review-history/64101)

Received 20 October 2020  
Accepted 27 December 2020  
Published 19 March 2021

*Corresponding author: E-mail: alolevo@yahoo.com, alonge.ivo@ubuea.cm;
ABSTRACT

Background: The human immunodeficiency virus (HIV) and Helicobacter pylori (H. pylori) are associated with significant chronic inflammation of the gastric mucosa. Gastric inflammation is a precursor to many gastrointestinal disorders including, peptic ulcer disease, atrophic gastritis (AG) and gastric cancer (GC). AG is usually accompanied by low hydrochloric acid (hypochlorhydria), low pepsinogens (PG) and high gastrin (G) levels and is the most significant risk condition for GC. Acid-free stomach is a risk factor for impaired drug absorption including anti-retroviral therapy and antibiotics. The role of H. pylori infection in HIV-infected subjects has been conflicting.

Objectives: We assessed the prevalence of H. pylori infection, AG and acid-free stomach (hypochlorhydria) amongst HIV/AIDS subjects in Yaounde Cameroon.

Methods: HIV/AIDS subjects were recruited during January-May 2018. Clinical and socio-demographic data of the subjects were recorded. An aliquot of 5 ml of blood was aseptically collected for analysis by GastroPanel® biomarker test for PG I, PG II, G-17 and H. pylori IgG antibodies. GastroPanel results were interpreted using the software application GastroSoft®. Statistical analyses were run by Epiinfo7.0. Ethical clearance was obtained from the National Ethics Committee.

Results: A total of 84 subjects were recruited, aged between 17-63 years (mean 37.6 ± 8.9 years). H. pylori seropositivity (IgG ≥30 EIU) was detected in 68(81.0%) of the subjects. H. pylori seropositivity was closely associated with low CD4 counts (p=0.01). Altogether, 26(31.0%) of the subjects presented with AG of the corpus while, hypochlorhydria was detected in 32(38.1%) of the patients. AG and hypochlorhydria were associated with low CD4 counts<200μl/l (p=0.01) and (p=0.005), respectively.

Conclusion: H. pylori infection, AG and acid-free stomach were common among HIV/AIDS patients, associated with an increased risk for GC and impaired absorption of micronutrients and some medicines.

Keywords: Helicobacter pylori; atrophic gastritis; hypochlorhydria; HIV; serological biomarkers.

1. INTRODUCTION

Human immunodeficiency virus (HIV) infection is common in Cameroon. It is estimated that over 600,000 persons live with HIV, with a population prevalence of 4.8%. Dyspepsia-like symptoms are very frequent amongst HIV/AIDS subjects during the course of their disease [1]. Helicobacter pylori (H. pylori) remains one of the most common infectious agents worldwide, with an estimated prevalence of >80% in certain underprivileged populations in Africa [2]. H. pylori-associated chronic active gastritis usually progresses into atrophic gastritis (AG) and acid-free or hypochlorhydric stomach, both being well established risk factors of gastric cancer (GC) [3].

HIV and H. pylori are associated with marked chronic inflammation of the gastric mucosa. Once progressed to AG, this chronic inflammation leads to hypochlorhydria and finally acid-free stomach, characterized by low serum levels of pepsinogen I and II (PG I and PGII), and refractory elevation of serum gastrin levels. Apart from GC, acid-free stomach is a risk factor for enteric infections and impaired absorption of drugs, including those used in anti-retroviral therapy and antibiotics [4].

Gastrins are peptide hormones that stimulate gastric acid (HCl) output by gastric parietal cells, the biologically most active being gastrin-17 (G-17). G-17 release by G-cells in the gastric antrum is stimulated by the presence of food in the stomach [5-8]. G-17 release is also regulated by feedback inhibition via somatostatin from the adjacent D-cells in the presence of a low gastric pH [9]. High fasting blood levels of G-17 are typical to patients with chronic gastritis (caused by H. Pylori infection or autoimmune disease) [9,10]. Chronic AG leads to the loss of parietal cells in the corpus, with hypochlorhydria, acid-free stomach and high G-17 levels as end results.

H. pylori infection itself can also cause mild increase of G-17, triggered by the inflammatory process in the mucosa [4]. Several studies have reported higher serum G-17 concentrations among HIV-positive patients [11,12] while one study failed to demonstrate any effect of THE HIV-status on serum gastrin levels [13]. The role of H. pylori infection in HIV-infected subjects has been conflicting. Several studies have reported...
low prevalence of *H. pylori* amongst HIV- positive subjects [1,2,14-17]. In contrast, higher *H. pylori* prevalence has been reported in some other studies [4,18,19].

Endoscopy with targeted mucosal biopsies is effective in screening of the upper GI-tract malignancies. However, this invasive method is uncomfortable, distressing and quite costly, emphasizing the need for rapid, reliable and inexpensive non-invasive tests [20,21]. Recently, a plasma biomarker panel with combination of PGI,−PGII, G-17 and *H. pylori* IgG antibodies using an ELISA technique was developed, known as GastroPanel® test (BiohitOyj, Helsinki, Finland). GastroPanel is intended for the first-line diagnosis of dyspeptic patients and for screening of the risk groups of GC, i.e. to detect the subjects with AG [22-25]. In the present study, GastroPanel test was used to assess the prevalence of *H. pylori* infection, AG and hypochlorhydria HIV/AIDS patients (in Yaounde, Cameroon), with biomarker levels related to the CD4 counts.

2. METHODS

We undertook a cross sectional study and patients presenting with HIV/AIDS and followed up at the Jammot Hospital of Yaounde Cameroon and consented to participate were prospectively recruited during the five-month period January-May 2018. Authorizations were obtained at the Jammot Hospital of Yaounde, and ethical approval was granted by the National Ethics committee (No 0174/CRERSHC of February 05th 2018). All patients signed an informed consent.

Clinical and socio-demographic information of patients were recorded. As an essential anamnestic data for GastroPanel test, the participants were enquired for their intake of non-steroidal anti-inflammatory drugs, treatment of antibiotics, use of proton pump inhibitors (PPI), H2-receptor antagonists and anti-retroviral therapy.

For the GastroPanel test, an aliquot of 5 ml of blood was aseptically collected in EDTA anticoagulated tubes, which was kept undisturbed for 1 hour for plasma formation. The tubes were subsequently centrifuged at 1500rpm for 5 minutes. The plasma obtained was transferred into sterile cryotubes and stored at - 20°C, for GastroPanel analysis, following the manufacturer’s instructions. The biomarker profiles for PGI, PGII, G-17, and *H.pylori* IgGwere interpreted using theGastroSoft software application [26]. All patients with *H. pylori* IgG≥ 30 EIU were considered positive for *H. pylori* infection. All patients with PGI < 30 μg/l and/or PGII < 3.0 and those with G-17 < 1pmol/l were considered positive for AG of the corpus and AG of the antrum, respectively. Subjects with G-17 >7pmol/l were considered as having hypochlorhydria.

All statistical analyses were conducted by Epi Info software 7.0 (the Centers for Disease Control and Prevention, CDC, Atlanta, GA, USA). All statistics were realized at 95% CI and a p-value <.05 was regarded as statistically significant.

3. RESULTS

Altogether, 84 subjects with HIV/AIDS were recruited, aged between 17-63 years, with a mean age of 37.6 ± 8.9 (SD) years. Of the 84 patients, 54(64.3%) were females (aged 21-63,mean 36.7 ± 8.6 years) and 30(35.7%) were males aged 17-60, mean 39.1 ± 9.6 years. Elevated levels of Anti *H. pylori* antibodies (IgG ≥ 30 EIU) were detected in 68/84 (81.0%) of the patients. In all age groups, higher seroprevalence of anti *H. pylori* antibodies were noticed in the HIV subjects Table 1, with *H. pylori* seroprevalence of 83.3%, 77.3% and 100.0% in HIV+ age groups 17-35, 36-54 and 55-73 years, respectively (p=0.48). *H. pylori* IgG seropositivity was not associated with the sex; females (85.2%) and males (73.3%), (p=0.10). *H. pyloriseropositivity was significantly associated with low CD4 counts ( p=0.01). When AG was classified into various grades, 52(63.9.0%) were classified into various grades, 52(63.9.0%) were presented with non-atrophic (superficial Hp-gastritis) while 26(31.0%) were diagnosed with AGof the corpus. In addition, 32(38.1%) of the subjects presented with hypochlorhydria Table 2. AG and hypochlorhydria were associated with low CD4 counts<200μl/l (p=0.01) and (p=0.005), respectively. High G-17 levels (G-17 >7pmol/l) were more frequently associated with AG of the corpus than with superficial gastritis (16.44±18.40 vs. 10.03±9.2pmol/l; p=0.03). The same is true with G-17 levels and hypochlorhydria as compared with normal acid levels (15.26±16.73 vs. 10.02± 9.73pmol/l).

4. DISCUSSION

The role of *H. pylorinfusion* among HIV-infected subjects remains controversial [1,19]. In the present study, seropositivity of *H. Pylori* was
68/84 (81.0%), which is very similar as previously reported among dyspeptic subjects in Cameroon [27] (81.40%), [28] (79.80%), [22] (78.7%) and in some other countries e.g. 76.5% in Kazakhstan [20]. This H. pylori seroprevalence is also similar with that (80.5%) reported previously among diabetic subjects in our country [29]. This high prevalence of H. pylori among HIV/AIDS subjects is in alignment with the figures reported from other countries including: 76.5% in Kazakhstan [20].

However, the seroprevalence of 81% in the present study is substantially higher than detected among HIV/AIDS patients in some other countries using different detection techniques, including histology and a rapid urease test (RUT) in Cameroon (59%) [30], and 60% [31], respectively. The figures were even lower (37.2%) in Brasil [15], those obtained by histology(22.1%) in China [14]; stool antigen test (SAT) in Uganda(22.5%) [17], or those (46.8%) in Nigeria [16]. Undoubtedly, these divergent figures in the prevalence of H. pylori reported among HIV-subjects are due to different diagnostic techniques. Histology, UBT and SAT used in most studies are associated with false negative results especially in certain medical conditions such as peptic ulcer, AG, MALT lymphoma and partial gastrectomy [24,25,31-34]. In addition, decreased bacterial load may result from prolonged use of certain medications with antimicrobial properties including PPI, NSAIDS and antibiotics, and lead to false negative results in many studies [24]. On the other hand, UBT may also give false positive results in cases where acid-free stomach is colonized by urease-positive bacterial species other than H. pylori [35]. These false negative and false positive results in H. pylori diagnosis can now be avoided with the simple GastroPanel test [23,24,35].

Table 1. Sociodemographic data of the HIV- subjects related to H. pylori serostatus

<table>
<thead>
<tr>
<th>Parameter</th>
<th>H.pylori Positive (IgG≥30EIU)</th>
<th>H.pylori Negative (IgG&lt;30EIU)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pepsinogen (PGI/µg/l)</td>
<td>94.63±87.73</td>
<td>126.8±126.2</td>
<td>0.23</td>
</tr>
<tr>
<td>Pepsinogen (PGII/µg/l)</td>
<td>50.53±38.06</td>
<td>30.18±24.63</td>
<td>0.045</td>
</tr>
<tr>
<td>PGI/PGII ratio</td>
<td>4.49±11.07</td>
<td>3.68±1.33</td>
<td>0.80</td>
</tr>
<tr>
<td>Gastrin-17 (G17/pmol/L)</td>
<td>13.2±14.23</td>
<td>7.76±2.79</td>
<td>0.15</td>
</tr>
<tr>
<td>H. pylori (IgG/EIU)</td>
<td>260.27±203.27</td>
<td>21.00±4.78</td>
<td>0.0001</td>
</tr>
<tr>
<td>CD4</td>
<td>54(84.4%)</td>
<td>10(15.6%)</td>
<td>0.01</td>
</tr>
<tr>
<td>0-199</td>
<td>10(83.3%)</td>
<td>2(16.7%)</td>
<td></td>
</tr>
<tr>
<td>200-499</td>
<td>2(33.3%)</td>
<td>4(66.7%)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>22(73.3%)</td>
<td>8(26.7%)</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>46(85.2%)</td>
<td>8(14.8%)</td>
<td></td>
</tr>
<tr>
<td>Age(yrs)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-35</td>
<td>30(83.3%)</td>
<td>6(16.7%)</td>
<td>0.48</td>
</tr>
<tr>
<td>36-54</td>
<td>34(77.3%)</td>
<td>10(22.7%)</td>
<td></td>
</tr>
<tr>
<td>55-73</td>
<td>4(100%)</td>
<td>0(0.0%)</td>
<td></td>
</tr>
<tr>
<td>ATB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>26(76.5%)</td>
<td>8(23.5%)</td>
<td>0.20</td>
</tr>
<tr>
<td>No</td>
<td>42(84.0%)</td>
<td>8(16.0%)</td>
<td></td>
</tr>
<tr>
<td>NSAIDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4(50%)</td>
<td>4(50%)</td>
<td>0.04</td>
</tr>
<tr>
<td>No</td>
<td>64 (84.2%)</td>
<td>12 (15.8%)</td>
<td></td>
</tr>
<tr>
<td>PPI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>22(100%)</td>
<td>0(0%)</td>
<td>0.004</td>
</tr>
<tr>
<td>No</td>
<td>46(74.2%)</td>
<td>16(25.8%)</td>
<td></td>
</tr>
<tr>
<td>HAART</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>18(69.2%)</td>
<td>8(30.8%)</td>
<td>0.07</td>
</tr>
<tr>
<td>No</td>
<td>50(86.2%)</td>
<td>8(13.8%)</td>
<td></td>
</tr>
</tbody>
</table>

ATB: antibiotics, NSAIDS: non steroidal anti inflammatory drugs, PPI: proton pump inhibitors, HAART: highly active antiretroviral therapy
Table 2. Atrophic gastritis (AG) and hypochlorhydria in HIV-positive subjects

<table>
<thead>
<tr>
<th></th>
<th>Atrophic Gastritis C: (PGI &lt; 30 µg/l)</th>
<th>Non atrophic Gastritis S: 58 (69.0%)</th>
<th>p-value</th>
<th>Hypochlorhydria Yes (G17 &gt; 7 pmol/l)</th>
<th>Hypochlorhydria No 52 (61.9%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pepsinogen PGI (µg/l)</td>
<td>26.37 ± 8.93</td>
<td>133.31 ± 99.84</td>
<td>0.00001</td>
<td>56.32 ± 86.12</td>
<td>128.2 ± 92.4</td>
<td>0.001</td>
</tr>
<tr>
<td>Pepsinogen PGII (µg/l)</td>
<td>42.29 ± 41.58</td>
<td>48.61 ± 34.43</td>
<td>0.47</td>
<td>42.14 ± 39.92</td>
<td>49.42 ± 34.59</td>
<td>0.38</td>
</tr>
<tr>
<td>PGII/PGI ratio</td>
<td>1.19 ± 1.02</td>
<td>5.62 ± 11.75</td>
<td>0.06</td>
<td>1.74 ± 1.49</td>
<td>5.79 ± 12.41</td>
<td>0.07</td>
</tr>
<tr>
<td>Gastrin-17 G17 (pmol/l)</td>
<td>16.44 ± 18.40</td>
<td>10.03 ± 9.2</td>
<td>0.03</td>
<td>15.26 ± 16.73</td>
<td>10.02 ± 9.73</td>
<td>0.07</td>
</tr>
<tr>
<td>H. pylori IgG (EIU)</td>
<td>204.4 ± 254.9</td>
<td>219.3 ± 181.7</td>
<td>0.76</td>
<td>170.8 ± 239.7</td>
<td>241.7 ± 178.7</td>
<td>0.13</td>
</tr>
<tr>
<td>CD4</td>
<td>26 (40.6%)</td>
<td>38 (59.4%)</td>
<td>0.005</td>
<td>28 (43.8%)</td>
<td>36 (56.3%)</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>0 (0%)</td>
<td>12 (100%)</td>
<td>0(0%)</td>
<td>0.00</td>
<td>12 (100%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0 (0%)</td>
<td>6 (100%)</td>
<td></td>
<td>4 (66.7%)</td>
<td>2 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>10 (33.3%)</td>
<td>20 (66.7%)</td>
<td>0.36</td>
<td>12 (40.0%)</td>
<td>18 (60.0%)</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td>16 (29.6%)</td>
<td>38 (70.4%)</td>
<td></td>
<td>20 (37.0%)</td>
<td>34 (63.0%)</td>
<td></td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>14 (38.29%)</td>
<td>22 (61.71%)</td>
<td>0.21</td>
<td>16 (44.4%)</td>
<td>20 (55.6%)</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>12 (27.3%)</td>
<td>32 (72.7%)</td>
<td></td>
<td>16 (36.4%)</td>
<td>28 (63.6%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0 (0%)</td>
<td>4 (100%)</td>
<td></td>
<td>0 (0%)</td>
<td>4 (100%)</td>
<td></td>
</tr>
</tbody>
</table>
Although the majority of *H. pylori* infections and AG have been associated with age and male gender [9,36,37], we did not find any association of *H. pylori* prevalence with age (p=0.48) or sex (p=0.10). However, we observed an elevated *H. pylori* prevalence among subjects with low CD4 (p=0.01) Table 1. This observation was not confirmed in some studies [1,2,30]. Given that *H. pylori* infection is usually contracted at childhood, it could have facilitated the destruction of CD4 cells by HIV-virus. According to Magen et al. [18], *H. pylori* stimulates the activation of CD4+, CCR5+ and CCR4+ which are receptors and co-receptors for HIV.

In the present analysis of GastroPanel biomarker profile, AG of the corpus occurred in 26 (31.0%) of the subjects (PGI <30μg/l) and low acid output (hypochlorhydria) in 32 (38.1%) (G-17>7pmol/l) of the study subjects. This high prevalence of AG of the corpus and hypochlorhydria among HIV subjects substantiate the figures reported in previous studies [1,15,30]. Such a high prevalence of AG is, however, in contrast to what has been reported among dyspeptic subjects [22,23,27,28,38,39,40]. This high prevalence (>30%) of corpus AG implicates that HIV/AIDS patients are at substantially higher risk of GC as compared to the general population.

In addition, we observed a close association between low CD4 counts and 1) AG (p=0.005) as well as 2) hypochlorhydria (p=0.01). Similar observations have been reported before [4,30]. AG and hypochlorhydria (low acid output) observed in HIV/AIDS subjects may suggest the risk of enteric infections, poor absorption of ARV, Vitamin-B12, and certain divalent micronutrients including iron, calcium, magnesium and zinc [3-10,41], with increased risk of clinically important sequels, like cognitive disorders, neurodegenerative and vascular disorders, encephalopathies, anemias and osteoporosis.

5. CONCLUSIONS

We report high prevalence of *H. pylori* infection amongst HIV/AIDS subjects similar to those in dyspeptic and diabetic subjects. We also report high prevalence of atrophic corpus gastritis and hypochlorhydria in these patients. *H. pylori* infection and AG represent the most important risk factors for GC and oesophageal cancer. Accordingly, HIV/AIDS subjects may be at increased risk of GC and impaired absorption of micronutrients and some medicines, thus requiring continuous monitoring and follow-up. This can be neatly accomplished by non-invasive GastroPanel test, closely reflecting both the structure and function of the stomach, in addition of being the most comprehensive test for *H. pylori* infections, devoid of the limitations of UBT and SAT tests [35].

CONSENT AND ETHICAL APPROVAL

Ethical clearance was obtained from the Regional Committee for Research on Human Health (CRERSH) No 0174/CRERSHC/2018 of 05 February 2018. An authorization was obtained from the authorities of the Jamot Hospital of Yaounde. All patients signed an informed consent form.

DECLARATION

Availability of data and materials: All data used during the current study are available from the corresponding author on reasonable request.

ACKNOWLEDGEMENTS

We thank the staff of the Haematology unit of the Jamot Hospital of Yaounde for their technical assistance.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


